Immunophenotypic analyses of CD34(+) cell subsets in bone marrow from HIV-infected patients during highly- active antiretroviral therapy.
BACKGROUND
Because increased bone marrow lymphopoiesis might contribute to immunologic reconstitution during highly-active antiretroviral therapy (HAART), we examined the effect of HAART on CD34(+) cell subsets in bone marrow from HIV-infected patients.


METHODS
In 12 HIV-infected patients, bone marrow and peripheral blood were collected before then 4 and 26 weeks after initiating HAART. Bone marrow in 28 HIV-seronegative controls was also examined. Immunophenotypic analyses of CD34(+) cell subsets in bone marrow were performed by flow cytometry.


RESULTS
Our main findings in bone marrow were: (i) HIV-infected patients had increased proportions of CD34(+)cells expressing T- and B-cell markers before initiating HAART; (ii) in contrast, these patients had decreased proportions of CD34(+) cells expressing myeloid-associated markers; (iii) although HAART induced an increase in peripheral T-cell counts, the percentage of CD34(+)cells expressing T-cell markers tended to decrease during such therapy; (iv) HAART induced a decrease in serum IgG accompanied by a slight decrease in the proportion of CD34(+)cells expressing B-cell markers; (v) in contrast, HAART induced a significant increase in peripheral granulocyte counts, accompanied by a slightly increased proportion of CD34(+) cells expressing myeloid-associated molecules.


CONCLUSIONS
Our findings are compatible with an HIV-related block in T-cell differentiation, leading to accumulation of T-cell progenitors in bone marrow, and such a block may be removed by HAART.
Müller
F
F
The National Hospital, University of Oslo, Norway.
Tjønnfjord
G E
GE
Nordøy
I
I
Kvale
D
D
Mellbye
O J
OJ
Aukrust
P
P
Frøland
S S
SS
D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis*; D023241:Antiretroviral Therapy, Highly Active; D001854:Bone Marrow Cells / Q000276:immunology*; D016022:Case-Control Studies; D005260:Female; D005434:Flow Cytometry; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016130:Immunophenotyping; D019469:Indinavir / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D018119:Stavudine / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D015215:Zidovudine / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000097:blood
D018952:Antigens, CD34; D017320:HIV Protease Inhibitors; D007074:Immunoglobulin G; D001613:beta 2-Microglobulin; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D018119:Stavudine